Sachs and Shudan’s teams utilized PDOs as platforms for drug screening to evaluate the sensitivity of HER2+ BC patients to HER2-targeted therapies and assess their responses to neoadjuvant chemotherapy. The gene discussed is ERBB2; the disease is breast cancer.